XTAEBCUR
Market cap5mUSD
Dec 24, Last price
20.40ILS
1D
-1.45%
1Q
-23.88%
IPO
-97.01%
Name
Erika B-Cure Laser Ltd
Chart & Performance
P/E
—
P/S
71.11
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
0.07%
Rev. gr., 5y
-3.40%
Revenues
30m
-39.63%
Net income
-19m
L-56.33%
CFO
-9m
L-73.45%
Earnings
Mar 17, 2025
Profile
Erika B-Cure Laser Ltd develops, manufactures, markets, distributes, and sells the B-Cure laser products in Israel and internationally. It offers B-Cure Laser Classic, a home medical device for the treatment of pain, orthopedic problems, dermatology, analgesia, inflammation, and wound healing; and B-Cure Laser Pro, a device for the treatment of acute and chronic problems, such as orthopedic problems, diabetic wounds, and difficulties in healing and mucositis. The company also provides B-Cure Laser Sport, a home device for treating injuries and sports pain, orthopedics, and others; and B-Cure Laser Sport Pro, a professional device for treating sports injuries, and pain relief in areas of the body and muscles, as well as infections, including Achilles tendonitis. In addition, it offers B-Cure Laser Dental, a device for use in dental clinics to treat dental problems, relieve gum pain, and inflammation, as well as helps in the recovery process after dental treatment, including implants, and in reducing pain and swelling; and B-Pro Dental Laser Cure, a device for the treatment of dental problems and infections in dental clinics. The company was formerly known as Erica Carmel Ltd and changed its name to Erika B-Cure Laser Ltd in January 2022. Erika B-Cure Laser Ltd was incorporated in 2007 and is headquartered in Haifa, Israel.
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 29,883 -39.63% | 49,496 -53.09% | 105,515 23.02% | |||
Cost of revenue | 31,211 | 42,238 | 71,950 | |||
Unusual Expense (Income) | ||||||
NOPBT | (1,328) | 7,258 | 33,565 | |||
NOPBT Margin | 14.66% | 31.81% | ||||
Operating Taxes | 1,371 | 28 | ||||
Tax Rate | 18.89% | 0.08% | ||||
NOPAT | (1,328) | 5,887 | 33,537 | |||
Net income | (19,221) -56.33% | (44,016) 354.15% | (9,692) -177.77% | |||
Dividends | (4,909) | |||||
Dividend yield | 1.06% | |||||
Proceeds from repurchase of equity | 12 | 83,337 | ||||
BB yield | -0.06% | -17.99% | ||||
| Debt | ||||||
Debt current | 2,353 | 4,322 | 5,355 | |||
Long-term debt | 6,478 | 13,401 | 25,536 | |||
Deferred revenue | ||||||
Other long-term liabilities | 1,040 | 1,130 | 1,763 | |||
Net debt | (1,733) | (2,190) | (31,057) | |||
| Cash flow | ||||||
Cash from operating activities | (8,973) | (33,798) | (28,749) | |||
CAPEX | (274) | (732) | (1,085) | |||
Cash from investing activities | 8,156 | (14,670) | (2,626) | |||
Cash from financing activities | (4,174) | (6,613) | 77,962 | |||
FCF | 12,193 | 7,098 | 16,638 | |||
| Balance | ||||||
Cash | 10,564 | 19,913 | 61,948 | |||
Long term investments | ||||||
Excess cash | 9,070 | 17,438 | 56,672 | |||
Stockholders' equity | (64,369) | (45,465) | 2,067 | |||
Invested Capital | 94,086 | 99,658 | 104,815 | |||
ROIC | 5.76% | 55.80% | ||||
ROCE | 13.39% | 31.40% | ||||
| EV | ||||||
Common stock shares outstanding | 103,897 | 104,057 | 102,021 | |||
Price | 0.20 -95.66% | 4.54 | ||||
Market cap | 20,499 -95.57% | 463,176 | ||||
EV | 18,309 | 432,119 | ||||
EBITDA | 860 | 10,371 | 36,396 | |||
EV/EBITDA | 1.77 | 11.87 | ||||
Interest | 396 | 617 | 575 | |||
Interest/NOPBT | 8.50% | 1.71% | ||||